01:31:38 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-01-10 Årsstämma 2024
2023-10-11 Bokslutskommuniké 2023
2023-07-07 Kvartalsrapport 2023-Q3
2023-04-12 Kvartalsrapport 2023-Q2
2023-01-12 Ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 Kvartalsrapport 2023-Q1
2023-01-11 Årsstämma 2023
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamma inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget är verksamma inom den skandinaviska marknaden. Newbury Pharmaceuticals har sitt huvudkontor i Lund.
2022-02-04 11:45:00

Newbury Pharmaceuticals is pleased to announce the Marketing Approval (MA) of Ticagrelor Newbury in Norway as the first country in a Scandinavian registration procedure. Approvals in Denmark and Sweden are expected to follow upon finalized national reviews.

Ticagrelor is used together with aspirin (acetylsalicylic acid) to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) such as heart attacks or strokes. It is used in adults with acute coronary syndrome, a group of conditions in which blood flow in the vessels supplying the heart is blocked so heart tissue cannot work properly or dies, and which includes heart attack and unstable angina (a severe type of chest pain). Ticagrelor is also used in adults who had a heart attack a year or more ago and are at a high risk of an atherothrombotic event. The medicine is only available on prescription.

The originator “Brilique”, marketed by AstraZeneca, is estimated to generate annual sales of app. 19 MEUR (source: DLMI Nordic Pharma Insights) across Scandinavia and launch of Ticagrelor Newbury is planned for 2025.

“We are pleased to see our portfolio of products being approved by the Health Authorities. The approval of Ticagrelor Newbury is our second product approval with additional product approvals expected during the year”, says Lars Minor - CEO, Newbury Pharmaceuticals.